. 2017 Jan 1;8(1):29–38. doi: 10.7150/jca.16822

Table 4.

Selected immune therapy in clinical trials with SCLC.

Author	Target	Drugs	Phase	Results
Grant et al.⁽⁸²⁾	Vaccine	BEC2/BCG	II	11 months (median RFS) for ED-SCLC
Giaccone et al.⁽⁸³⁾	Vaccine	BEC2/BCG vs. observation	III	14.3 vs. 16.4 months (median OS, P = 0.28)
Antonia et al.⁽⁸⁴⁾	Vaccine	P53	I	11.8 months (median OS)
Chiappori et al.⁽⁸⁵⁾	Vaccine	INGN-225	I/II	8.8 months (median OS)
Zarogoulidis et al.⁽⁸⁶⁾		CT vs. CT + IFN-α vs. CT+ IFN-γ vs. CT + IFN-α + IFN-γ	II	19.0 vs. 34.0 vs. 17.0 vs. 13.6 months (median OS, P<0.05) for LD-SCLC
Pillai et al.⁽⁸⁷⁾		IFN	II	6.2 months (median OS)
Pillai et al.⁽⁸⁷⁾		IFN	II	2.0 months (median PFS)
Ott et al.⁽⁹³⁾	PD-1	Pembrolizumab	I	35% (ORR)
Antonia et al.⁽⁹⁵⁾	PD-1/CTLA-4	Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg	I/II	23% (ORR)
Reck et al.⁽⁹⁷⁾	CTLA-4	^dControl vs. Concurrent Ipilimumab vs. Phased Ipilimumab	II	9.9 vs. 9.1 vs. 12.9 (median OS)
Reck et al.⁽⁹⁷⁾	CTLA-4	^dControl vs. Concurrent Ipilimumab vs. Phased Ipilimumab	II	5.3 vs. 5.7 and 6.4 (median irPFS)

BCG: Bacillus Calmette-Guerin; RFS: relapse-free survival; ED-SCLC: extensive disease small cell lung cancer; CT: chemotherapy; LD-SCLC: extensive disease small cell lung cancer; IFN: Interferon; PD-1: programmed death-1; CTLA-4: cytotoxic T-lymphocyte antigen-4; irPFS: immune-related progression-free survival.

^dControl (paclitaxel-carboplatin + Ipilimumab + placebo); concurrent Ipilimumab (Ipilimumab+ paclitaxel-carboplatin followed by placebo + paclitaxel-carboplatin); Phased Ipilimumab (placebo + paclitaxel-carboplatin followed by Ipilimumab+ paclitaxel-carboplatin).